On Jun. 1, 2020, Resverlogix announced that it is moving forward with a plan to further evaluate apabetaloneﾒs impact on COVID-19 in both a preclinical and clinical setting. A first step will be to investigate whether apabetalone treatment of human cells susceptible to 2019 novel coronavirus (2019-nCoV) infection will impact the replication cycle of the virus.

Initial work ﾖ undertaken in an approved Biological Safety Level 3 laboratory (BSL3) ﾖ commenced with additional work with other third-party laboratories expected. In parallel, cell factors critical to 2019-nCoV infection will be assessed in-house for apabetalone-mediated regulation.